Scinai Immunotherapeutics regains compliance with Nasdaq listing rule

seekingalpha08-29

Scinai Immunotherapeutics (NASDAQ:SCNI) has regained compliance with a Nasdaq listing rule that requires listed companies to maintain stockholders' equity of at least $2.5M. On August 21, 2024, the ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2463236045?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-08-29 19:15","share_image_url":"https://static.laohu8.com/5a36db9d73b4222bc376d24ccc48c8a4","id":"2463236045","market":"hk","top_or_hot":-1,"title":"Scinai Immunotherapeutics regains compliance with Nasdaq listing rule","media":"seekingalpha","content":"<div>\n<p>Scinai Immunotherapeutics (NASDAQ:SCNI) has regained compliance with a Nasdaq listing rule that requires listed companies to maintain stockholders' equity of at least $2.5M. On August 21, 2024, the ...</p>\n\n<a href=\"https://seekingalpha.com/news/4144989-scinai-immunotherapeutics-regains-compliance-with-nasdaq-listing-rule\">Source Link</a>\n\n</div>\n","source":"seekingalpha","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Scinai Immunotherapeutics regains compliance with Nasdaq listing rule</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nScinai Immunotherapeutics regains compliance with Nasdaq listing rule\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-08-29 19:15 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://seekingalpha.com/news/4144989-scinai-immunotherapeutics-regains-compliance-with-nasdaq-listing-rule><strong>seekingalpha</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Scinai Immunotherapeutics (NASDAQ:SCNI) has regained compliance with a Nasdaq listing rule that requires listed companies to maintain stockholders' equity of at least $2.5M. On August 21, 2024, the ...</p>\n\n<a href=\"https://seekingalpha.com/news/4144989-scinai-immunotherapeutics-regains-compliance-with-nasdaq-listing-rule\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU2210150020.SGD","symbol_name":"Natixis Thematics Subscription Economy R/A SGD","start_time":0,"source_url":"https://seekingalpha.com/news/4144989-scinai-immunotherapeutics-regains-compliance-with-nasdaq-listing-rule","article_id":"2463236045","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2463236045","pubTimestamp":1724930114,"columns":[],"sourceInfo":{"source_id":"seekingalpha","name":"Seeking Alpha"},"weMediaInfo":null,"summary":"Scinai Immunotherapeutics  has regained compliance with a Nasdaq listing rule that requires listed companies to maintain stockholders' equity of at least $2.5M. On August 21, 2024, the company closed a loan restructuring agreement with European Investment Bank, converting around $29M of debt to preferred equity and leaving a debt balance of 250,000 , as a result of which it now has stockholders' equity above $2.5M.   The biopharmaceutical company is now back in full compliance with all Nasdaq listing requirements.","collect":0,"end_time":0,"defaultTopTitle":"seekingalpha.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"LU2210150020.SGD":"Natixis Thematics Subscription Economy R/A SGD","LU2210149790.SGD":"Natixis Thematics Subscription Economy R/A SGD-H","IE00BKPKM429.USD":"NEUBERGER BERMAN GLOBAL SUSTAINABLE EQUITY \"A\" (USD) ACC","BK4588":"碎股",".IXIC":"NASDAQ Composite","SCNI":"Scinai Immunotherapeutics Ltd.","QID":"纳指两倍做空ETF","NDAQ":"纳斯达克OMX交易所","TQQQ":"纳指三倍做多ETF","BK4112":"金融交易所和数据","PSQ":"纳指反向ETF","QLD":"纳指两倍做多ETF","BK4585":"ETF&股票定投概念","BK4139":"生物科技","SQQQ":"纳指三倍做空ETF","BK4007":"制药","LU2095319765.USD":"Natixis Thematics Subscription Economy R/A USD"},"translate_title":"Scinai Immunotherapeutics重新遵守纳斯达克上市规则","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"SCNI":1,"NQmain":1,"NDAQ":1,".IXIC":1,"TQQQ":0.6,"SQQQ":0.6,"QLD":0.6,"QID":0.6,"PSQ":0.6,"MNQmain":0.6},"content_text":"Scinai Immunotherapeutics (NASDAQ:SCNI) has regained compliance with a Nasdaq listing rule that requires listed companies to maintain stockholders' equity of at least $2.5M. On August 21, 2024, the company closed a loan restructuring agreement with European Investment Bank, converting around $29M of debt to preferred equity and leaving a debt balance of €250,000 (approximately $273,000), as a result of which it now has stockholders' equity above $2.5M.   The biopharmaceutical company is now back in full compliance with all Nasdaq listing requirements.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.3","shortVersion":"4.29.3","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2463236045"}